About TearScience
TearScience is a company based in Morrisville (United States) founded in 2005 was acquired by Johnson & Johnson Vision in September 2017. TearScience has raised $150.73 million across 5 funding rounds from investors including HealthCare Royalty Partners, De Novo Ventures and Spray Venture Partners. The company has 35 employees as of December 31, 2019. TearScience offers products and services including ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System. TearScience operates in a competitive market with competitors including Bruder Healthcare, Oculeve, Tear Film Innovations, Eyedetec Medical and Sinopsys Surgical, among others.
- Headquarter Morrisville, United States
- Employees 35 as on 31 Dec, 2019
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tearscience, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$150.73 M (USD)
in 5 rounds
-
Latest Funding Round
$19.23 M (USD), Series D
Apr 12, 2016
-
Investors
HealthCare Royalty Partners
& 7 more
-
Employee Count
35
as on Dec 31, 2019
-
Acquired by
Johnson & Johnson Vision
(Sep 08, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TearScience
TearScience offers a comprehensive portfolio of products and services, including ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System.
Provides vision correction and eye health support for patients.
Offers tools to manage and prevent myopia progression.
Enables efficient ordering of products for eye care professionals.
Funding Insights of TearScience
TearScience has successfully raised a total of $150.73M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $19.23 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TearScience
TearScience has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HealthCare Royalty Partners, De Novo Ventures and Spray Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for TearScience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TearScience
Investment portfolio details for TearScience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TearScience
Detailed financials for TearScience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tearscience Comparisons
Peer comparison for TearScience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TearScience
TearScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bruder Healthcare, Oculeve, Tear Film Innovations, Eyedetec Medical and Sinopsys Surgical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for dry eye and pain management are developed.
|
|
| Locked | Locked | Locked |
A non-invasive nasal device for dry eye treatment is developed.
|
|
| Locked | Locked | Locked |
Evaporative dry eye is treated through meibomian gland stimulation devices.
|
|
| Locked | Locked | Locked |
Develops devices for the treatment of dry eyes
|
|
| Locked | Locked | Locked |
Offers lacrimal stents and procedures designed to effectively treat sinusitis.
|
Detailed competitors of TearScience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tearscience
Complete news archive for TearScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TearScience
TearScience was founded in 2005.
TearScience is headquartered in Morrisville, United States.
TearScience is a funded company, having raised a total of $150.73M across 5 funding rounds to date.
As of Dec 31, 2019, the latest employee count at TearScience is 35.
TearScience is a developer of devices that provide clinical identification and treatment of evaporative dry eye. Evaporative dry eye is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eyes natural tear film. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. The LipiFlow Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland while protecting the structures of the patients eye. TearSciences LipiFlow Thermal Pulsation System, Korb Meibomian Gland Evaluator, Lipi View products are FDA approved.
TearScience's top competitors include Oculeve, Tear Film Innovations and Bruder Healthcare.
TearScience offers ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System.
TearScience has 8 investors. Key investors include HealthCare Royalty Partners, De Novo Ventures, Spray Venture Partners, Investor Growth Capital, and unknown.